Current status and future directions of immune checkpoint inhibitors in EGFR-mutated advanced non-small cell lung cancer
10.3781/j.issn.1000-7431.2024.2401-0049
- VernacularTitle:免疫检查点抑制剂在表皮生长因子受体基因突变型晚期非小细胞癌中的应用现状与未来
- Author:
Xingyuan LI
1
;
Yongfeng YU
1
;
Shuya MU
1
;
Shun LU
1
Author Information
1. 上海交通大学医学院附属胸科医院肿瘤内科,上海 200030
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Epidermal growth factor receptor;
Immunotherapy;
Drug resistance
- From:
Tumor
2024;44(6):555-565
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor(EGFR)gene mutation is a common oncogenic driver mutation in non-small cell lung cancer(NSCLC).For patients with this gene mutation,the preferred first-line treatment is targeted therapy with an EGFR tyrosine kinase inhibitor,but the issues of drug resistance and disease progression will inevitably arise during the treatment.Standard platinum-based doublet chemotherapy regiment after failure of EGFR-TKIs has limited benefit,and more effective treatment strategies urgently need to be developed.In recent years,many studies have confirmed the efficacy of immunotherapy in NSCLC patients.Nevertheless,for advanced NSCLC patients with EGFR gene mutations,the efficacy of immunotherapy monotherapy is not satisfactory,thus immunotherapy-based combination therapy is receiving increasing attention.
